SEC Form 4 · accession 0001193125-26-307838
CG Oncology, Inc. · CGON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard E Post
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001991792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2026 | M | 1,000 | $0.60 | A | 1,000 | D | |
| Common Stock | Jul 15, 2026 | S | 1,000 | $71.17 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $0.60 | Jul 15, 2026 | M | 1,000 | D | — | Jul 8, 2028 | Common Stock | 1,000 | 105,077 | D |
Explanation of responses
- F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
- F2Fully vested